Начало・Списък с акции・AbCellera Biologics Inc

AbCellera Biologics Inc

Затворен

СекторЗдравеопазване

6.44 4.04

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

5.71

Максимум

6.55

Ключови измерители
By Trading Economics
Приходи	-34M -43M
Продажби	-37M 8.3M
EPS	-0.14
Марж на печалбата	-519.122
Служители	562
EBITDA	-23M -41M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+82.94% upside

Дивиденти
By Acuity
Следващи печалби	5.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	178M 1.8B
Предишно отваряне	2.4
Предишно затваряне	6.44

Настроения в новините

By Acuity

47%

53%

159 / 340 Класиране в Healthcare

AbCellera Biologics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.08.2026 г., 23:06 ч. UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

5.08.2026 г., 23:02 ч. UTC

Social Media

News

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

3.08.2026 г., 19:36 ч. UTC

Correlated Moves

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

31.07.2026 г., 19:33 ч. UTC

Correlated Moves

Social Media

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.

30.07.2026 г., 23:41 ч. UTC

Correlated Moves

Abcellera Biologics shares are lower in after-market trading, reflecting broader market volatility following the Federal Reserve's decision to maintain interest rates.

29.07.2026 г., 23:51 ч. UTC

Abcellera Biologics Inc. shares were roughly flat in after-market hours, with no specific news identified. The stock is down significantly from last month's close.

28.07.2026 г., 19:41 ч. UTC

News

Abcellera Biologics is rising, driven by gains in the Life Sciences Tools & Services sector and positive trends in the antibody therapeutics market.

27.07.2026 г., 19:46 ч. UTC

Correlated Moves

Abcellera Biologics Inc shares are higher, reflecting a modest increase since Friday's close. Broader market gains may influence sentiment in life sciences.

24.07.2026 г., 23:46 ч. UTC

Abcellera Biologics Inc shares are higher in after-market hours, showing resilience despite recent challenges in the bond market and declining prices.

22.07.2026 г., 20:06 ч. UTC

Abcellera Biologics Inc shares are lower today, reflecting broader market trends amid uncertainty ahead of the Federal Reserve meeting on July 29.

21.07.2026 г., 23:06 ч. UTC

Correlated Moves

Abcellera Biologics shares higher in after-market trading, maintaining strong performance since Tuesday's close, despite being below its 20-day moving average.

20.07.2026 г., 23:16 ч. UTC

Abcellera Biologics Inc. shares are roughly flat in after-market trading, remaining about 16.33% below their 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

AbCellera Biologics Inc Прогноза

Ценова цел

By TipRanks

82.94% нагоре

12-месечна прогноза

Среден 10.83 USD 82.94%

Висок 13 USD

Нисък 7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за AbCellera Biologics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на AbCellera Biologics Inc през последните 3 месеца.

Настроение

By Acuity

159 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.